HC Wainwright Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $100.00

Soleno Therapeutics (NASDAQ:SLNO) had its price objective lowered by investment analysts at HC Wainwright from $120.00 to $100.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 159.27% from the stock’s previous close. HC Wainwright also issued estimates for Soleno Therapeutics’ Q1 2026 earnings at $0.93 EPS, Q2 2026 earnings at $1.02 EPS and FY2027 earnings at $7.50 EPS.

A number of other brokerages have also recently issued reports on SLNO. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company dropped their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research report on Tuesday, January 13th. Finally, TD Cowen cut their target price on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.85.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $38.57 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a 12 month low of $32.63 and a 12 month high of $90.32. The company has a fifty day moving average price of $41.77 and a two-hundred day moving average price of $52.42. The company has a market cap of $1.99 billion, a PE ratio of 167.70 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Research analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On Soleno Therapeutics

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after buying an additional 189 shares during the period. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics in the second quarter valued at approximately $25,000. Avanza Fonder AB increased its stake in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock valued at $148,000 after acquiring an additional 323 shares during the period. Principal Financial Group Inc. increased its stake in shares of Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after acquiring an additional 340 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after purchasing an additional 360 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.